Quick Search 
Drugs of the Future
Register or sign in

Instructions for Authors 
  • Established: 1976

  • Published: 12 issues/year

  • Publishing model: Subscription-based

  • Reader profile: Medicinal chemists, pharmacologists, molecular biologists and other researchers involved in the design, discovery and development of drugs/biologicals, target identification and validation, and the preclinical and clinical development of treatments for both common and rare and neglected diseases and conditions, and corporate strategy directors

  • Indexed in: Current Contents® - Life Sciences, Biological Abstracts®, Chemical Abstracts®, EMBASE®, SCOPUS®, BIOSIS Previews®, Current Contents Connect™, Web of Science Core Collection™, Science Citation Index Expanded™ (SCIE), Journal Citation Reports™ (JCR)

  • p-ISSN: 0377-8282, e-ISSN: 2013-0368

Aims & Organization

Drugs of the Future is a peer-reviewed interdisciplinary biomedical research journal that publishes review articles on topics emerging from the confluence of scientific fields including chemistry, biology, pharmacology, genomics and medicine. The journal identifies and anticipates new trends, advances and breakthroughs in basic, translational and clinical research. It includes the following sections:

Monographs, containing comprehensive product information on new compounds in development, including synthesis, preclinical pharmacology, pharmacokinetics and metabolism, safety, clinical studies and drug interactions.

Review articles, highlighting therapeutic approaches for the treatment of diseases, compounds under development and those in clinical use.

Filling the Gaps in Drug Therapy, covering therapeutic progress in diseases and conditions, some rare and others all too common, for which no effective therapy currently exists, or for which existing therapies are poorly tolerated or otherwise unsatisfactory.

Targets to Watch, highlighting targets with potential in drug development.

Biomarkers to Watch, focusing on biomarkers undergoing early clinical evaluation for their use in diagnosis, treatment efficacy and target identification.

Pipeline on the Move, presented in tabular format, reporting on recent changes or milestones detected on the status of drugs currently under active development.

NME Digest, highlighting new, biologically active molecules revealed for the first time in current literature, at congresses and in company communications that are identified by a code number or the chemical name. They include compounds chosen for further pharmacological evaluation or as clinical candidates, new leads whose structural optimization could provide structural diversity of known mechanistic classes of drugs, and new pharmacological tools for investigating drug targets.

Congress/meeting reports, providing highlights from major scientific meetings around the world.

A yearly pharmacostructural index and a cumulative formula index.

The Editorial Board (listed below) comprises major authorities in their fields who are selected to ensure that a wide variety of therapeutic areas are covered. The Board members recommend reviews from authorities within their field to guarantee that all topics are covered comprehensively and that all issues of current importance are emphasized. Submitted articles are peer reviewed before publication.

Publication Ethics

Drugs of the Future follows the Core Practices and Guidelines of the Committee on Publication Ethics (COPE) as well as the Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals of the International Committee of Medical Journal Editors (ICMJE).

Authors and peer reviewers are expected to adhere to the highest ethical, scientific, and writing standards.

The ICMJE considers scientific misconduct in research and non-research publications to include, without being limited to, data fabrication; data falsification including deceptive manipulation of images; purposeful failure to disclose relationships and activities; and plagiarism. Allegations of scientific misconduct warrant investigation and possible manuscript rejection, correction, or retraction as well as notification of author institutions and funders.

In line with the ICJME, duplicate publication, or publication of a paper that overlaps substantially with one already published, should be communicated to the journal editor upon manuscript submission, whereupon the editor may decide to proceed with publication by including a clear statement that the author and editor are intentionally republishing an article. In general, manuscripts published previously in print or electronic format, or submitted for consideration elsewhere, are not acceptable.

Plagiarism is the use of any intellectual content from another author without clear attribution. This includes large amounts of text, images, and ideas as well as rephrasing of other's work or ideas. Re-use of text from an author's previous work without clear citation is self-plagiarism. Manuscripts including clear cases of plagiarism of any kind are not accepted by the journal.

Authors, peer reviewers and the journal editors are to protect the confidentiality of all aspects of manuscripts undergoing evaluation. All of these parties are also obliged to provide disclosures of any known or potential conflicts of interest, be they financial, professional, personal, or other, which may affect objectivity and the principle of providing accurate, complete, duly cited information and well-reasoned interpretations of that information to the scientific community and the public at large.

Diversity and inclusion are core values at Drugs of the Future, and the journal is committed to working with and valuing the contributions of the broadest array of authors, peer-reviewers, editorial staff, and editorial board members.

Peer Review Policy

Monographs and review articles in Drugs of the Future are subject to peer review, and publication of submitted manuscripts is contingent on the Editor in Chief’s approval and favorable peer review. Peer review of pieces is conducted by 2-3 reviewers after which authors are expected to revise their manuscript according to the reviews or explain any disagreement with specific reviewer comments.

Reviewers are selected based on specific area expertise and the journal editors appreciate conscientious, specific, and logical reviews as well as their timely completion.

Drugs of the Future follows a double-blind peer review process whereby the identity of reviewers is and remains confidential and interaction between reviewers and authors is mediated by journal editors. Peer reviews are not published and are owned by the authors of the reviews.

Reviewers are to protect the confidentiality of any information shared during peer review and to obtain written permission from the journal editor before sharing a manuscript under review for any purpose, e.g. seeking another expert opinion. Reviewers are prohibited from citing previously unpublished study results or incorporating unpublished results in their own work before those results are published.

Reviewers are also expected to disclose to the journal editors any potential conflicts of interest or any personal, financial, or professional factors which may limit objectivity. If a reviewer is aware of a potential conflict of interest, they should refuse the assignment. If the journal editor becomes aware of a potential conflict of interest the assignment may be terminated.

Click here for guides and training related to peer review.

Editorial Team

Editor in Chief: David Andreu, Professor of Chemistry, Department of Medicine & Life Sciences, Pompeu Fabra University, Barcelona, Spain

Managing Editor: Michelle K. Tracy

Assistant Editors: Pilar Avello, Xavier Bofill, Vanessa Carceller, Patrick Cole, Coia Dulsat, Dolors Fernández-Forner, Ann I. Graul, Esmeralda Rosa, Lisa Sorbera

Editorial Coordinator: Christine Todd

Scientific Advisory Board

Magid Abou-Gharbia (Temple University, USA)
Michael J. Aminoff (University of California, San Francisco, USA)
John K. Amory (University of Washington, USA)
Sabina Antoniu (Grigore T. Popa University of Medicine and Pharmacy, Romania)
Frank C. Barone (SUNY Downstate Medical Center, USA)
Helena Boshoff (LCIA, NIAID, NIH, USA)
David Brooks (Janssen Pharmaceutical Companies of Johnson & Johnson, USA)
Pier Paolo Claudio (University of Mississippi, USA)
Erik de Clercq (Katholieke Universität Leuven, Belgium)
Hans Jurgen Federsel (AstraZeneca, Sweden)
Prabha B. Fernandes (Cempra, Inc., USA)
Frederick W. Fraunfelder (Casey Eye Institute, USA)
Matthew Hall (NCI, NIH, USA)
David Howat (HBS Consulting, France)
Kurt Jarnagin (Anacor Pharmaceuticals, USA)
György M. Keserü (Hungarian Academy of Sciences, Hungary)
Shrinivas K. Kulkarni (Panjab University, India)
Philip L. Lorenzi (M.D. Anderson Cancer Center, USA)
James Mixson (University of Maryland, USA)
Hermann Mucke (HM Pharma Consultancy, Austria)
David Newman (NCI, USA)
Kenji Onodera (Spica Research, Japan)
Ramesh Panchagnula (Pfizer Pharmaceutical, India)
Mercè Pineda (Hospital Sant Joan de Déu, Spain)
Gaetano Romano (Temple University, USA)
J.K. Shen (Shanghai Institute of Materia Medica, China)
Zelalem Temesgen (Mayo Clinic, USA)
J.R. Wu-Wong (University of Illinois at Chicago/Vidasym, USA)
William C. Zamboni (University of North Carolina, USA)

© 2023 Clarivate. All rights reserved.
Copyright NoticeTerms of UsePrivacy StatementCookie PolicyManage cookie preferences